SCHEDULE: Millennium Management Discloses 5.6% Stake in Sutro Biopharma

Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have jointly disclosed a beneficial ownership of 5.6% of Sutro Biopharma, Inc.'s Common Stock.

Summary

• Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have filed a Schedule 13G, indicating their beneficial ownership in Sutro Biopharma, Inc.
• The reporting persons collectively beneficially own 4,717,215 shares of Sutro Biopharma, Inc.'s Common Stock.
• This aggregate amount represents 5.6% of the class of securities.
• The shares are held with shared voting power and shared dispositive power.
• The filing states that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that inherently conveys positive or negative sentiment regarding the issuer's performance or outlook.

Positives

• NA

Negatives

• NA

Risks

• NA

Future Outlook

This Schedule 13G filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from Sutro Biopharma, Inc. or the reporting persons regarding the issuer's future performance.

Management Comments

• Gil Raviv, Global General Counsel for Millennium Management LLC and Millennium Group Management LLC, certified that the information set forth in the statement is true, complete, and correct.
• Israel A. Englander certified that the information set forth in the statement is true, complete, and correct.

Industry Context

This filing represents a significant investment by a prominent hedge fund, Millennium Management, in a biopharmaceutical company. Such disclosures are common in the investment landscape, reflecting strategic positions taken by institutional investors in publicly traded companies, particularly in sectors like biopharma which can offer high growth potential.

Stakeholder Impact

• Shareholders: The disclosure of a new significant beneficial owner, Millennium Management, may influence market perception and trading activity for Sutro Biopharma, Inc.'s stock.

Key Dates

Keywords

Sutro Biopharma, Millennium Management, Schedule 13G, Beneficial Ownership, Common Stock, Biopharma, Investment, SEC Filing